Abstract: A readrRNA (RNA sensing by Endogenous ADAR) molecule is a modular RNA molecule that facilitates cell sensing and detection of a cell type or cell status and/or facilitates delivery of an effector protein to a selected cell. A composition that includes such a modular RNA molecule and another nucleic acid (linked or unlinked to the modular RNA molecule) is a CellREADR (Cell access through RNA sensing by Endogenous ADAR). readrRNA and CellReadR sense the presence of a selected cell RNA and leverages RNA editing mediated by ADAR (adenosine deaminase acting on RNA) for coupling the detection of a cell-defining RNA with translation of one or more effector proteins in a cell or in a mammal.

Abstract: Disclosed herein include methods, compositions, and kits enabling expression of multiple payload proteins from a single mRNA configured to achieve a predetermined stoichiometry of first unit payload protein(s) and second unit payload protein(s) in a cell or cell-like environment. There are provided, in some embodiments, nucleic acid compositions comprising a polynucleotide comprising a first nucleic acid unit (encoding one or more first unit payload protein(s)) and a second nucleic acid unit (encoding one or more second unit payload protein(s)). The first nucleic acid unit and the second nucleic acid unit can each comprise an engineered translation initiation site (eTIS) comprising a three-nucleotide tunable element immediately upstream of a start codon. In some embodiments, the nucleic acid composition comprises at least one modified nucleotide and/or at least one nucleotide analogue or nucleotide derivative. In some embodiments, the polynucleotide comprises a disclosed eTIS combination.

Abstract: Provided are an optimized CPY4V2 gene and an application thereof. The gene relates to a polynucleotide for coding a CYP4V2 protein, and comprises a nucleotide sequence having 90% or over 90% of identity with a nucleotide sequence as shown in SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9. Also provided is an expression vector comprising the gene. The expression vector can realize lasting and stable expression in retinal pigment epithelium of eyes, can effectively reduce the dosage and possible side effects of a gene therapy drug for treating BCD, and improves the therapeutic effect.

Abstract: Described herein are compositions and methods to modulate gene expression without permanently editing the genome. The compositions and methods may be useful to treat neurological diseases and pain.

Abstract: Provided herein are expression cassettes comprising at least one copy of an enhancer element, wherein the enhancer element comprises, consists essentially of, or consists a nucleotide sequence at least 50% identical to any one of SEQ ID NOS: 1-16 and vectors comprising the expression cassettes. Also provided herein are cells transduced with the expression cassettes or the vectors. Further described herein are pharmaceutical compositions comprising an effective amount of one or more of: the cell, the expression cassette, or the vector of this disclosure. Also disclosed herein are methods of treating a hemoglobinopathy in a subject, comprising administering an effective amount of the pharmacological compositions described herein.

Abstract: Methods, compositions, and systems for treating subject(s) in need of plasma Factor VIII, particularly a subject having preexisting anti-FVIII inhibitory antibodies, are provided. The methods involve administering to the subject a therapeutically effective amount of an inflammation suppressor, a therapeutically effective amount of a CD8+ T cell depleting agent, and a therapeutically effective amount of a composition comprising a lentiviral vector (LV) comprising an optimized FVIII expression cassette expressibly linked to a megakaryocyte-specific promoter. Such methods, compositions, and systems are useful to treat subjects with blood clotting disorder(s), such as hemophilia A.

Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a suspension of preformed lipid nanoparticles and mRNA.

Abstract: The invention relates to novel caging-group-free photactivatable fluorescent dyes having the structural formula (I) as well as to the corresponding photoactivated fluorescent dyes having the structural formula (II). The invention further relates to the use of the photoactivatable compounds as such or after photoactivation, in particular as fluorescent tags, analytical reagents and labels in optical microscopy, imaging techniques, protein tracking, nucleic acid labeling, glycan analysis, capillary electrophoresis, flow cytometry or as a component of biosensors, or as analytical tools or reporters in microfluidic devices or nanofluidic circuitry.

Abstract: The present invention relates to improved methods for obtaining purified contrast agents that are suitable for magnetic resonance imaging. The contrast agents are prepared by a method such dynamic nuclear polarization (DNP), hydrogenative parahydrogen induced polarization (PHIP), or Signal Amplification By Reversible Exchange (SABRE). High degrees of purity are achieved by performing an evaporation step to separate a signal enhanced precursor or the contrast agent from a metal catalyst or a source of radicals.

Abstract: In a method for preparing a hyperpolarised sample, for example for a magnetic resonance procedure, a starting solution comprising alpha-ketoglutaric acid and 13C-labelled molecules is frozen to form a frozen solution. The solution is irradiated with ultraviolet and/or visible radiation, to generate free radicals. The frozen solution is then hyperpolarised by applying a magnetic field to the solution while irradiating it with frequency-modulated microwave radiation.

Abstract: The present invention relates to the RRR/SSS pair of enantiomers of the of Gd(PCTA-tris-glutamic acid), the single enantiomers of the pair, the pharmaceutically acceptable salts thereof, their amide derivatives, and compositions comprising at least 50% of these compounds.

Abstract: The present invention relates to a method of removal of metal ion impurities, such as calcium, from lanthanide metal complexes of macrocyclic chelators. The method uses a scavenger resin to remove metal ions, displaced from chelator, by an excess of lanthanide ions. Also provided is a method of preparation of MRI contrast agents, from the purified lanthanide metal complex, by the addition of a defined excess chelator.

Abstract: The present invention relates to novel biocompatible imaging particles comprising superparamagnetic iron oxide (SPIO) assembled into submicromiter-sized clusters within a biodegradable polycathecolamine or polyserotonine matrix, their synthesis and use in imaging techniques. These particles overcome the issues of toxicity and unreliable signal of the molecules from the prior art by providing similar contrast to that of the microparticles of iron oxide and rapidly disassemble into isolated SPIO particles once they reach the acidic lysosomal compartment of the MPS cells, thus enabling their digestion.

Abstract: Described are coated iron oxide nanorods (IONRs) containing an iron oxide core and a coating surrounding the core, and pharmaceutical compositions containing these coated IONRs. The iron oxide core of the coated IONRs has strong magnetic property, i.e., a magnetic flux density of at least 10 emu/g, induced using 1 T magnetizing field strength, at room temperature. The coating of the coated IONRs can be formed by a polymer, such as an amphiphilic polymer. The coated IONRs are stable in an aqueous medium for at least 30 mins, at room temperature, while maintain the superior magnetic property of the core, achieving a separation efficiency of at least 80% within only 1 min of magnet time. Optionally, the coated IONRs contain one or more active agents embedded in the coating of the coated IONRs, for systemic or local delivery.

Abstract: An adoptive immunotherapy composition includes an enriched population of immune cells, wherein at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, or more immune cells include intracellular nanobubbles.

Abstract: Disclosed are compounds useful for imaging cells that overexpress FAP, and for treating cancer. Also disclosed are methods of making said compounds.

Abstract: The invention relates to a method of preparing an [18F] radio-labelled compound, wherein the water content is controlled. Controlling the water content and the origin of the water within the reaction process has a significant effect on both the yield and the purity of the product of the radio-labelling process.

Abstract: An inhibitor of a prostate specific membrane antigen and a pharmaceutical use thereof. Specifically, the present solution belongs to the field of radiopharmaceuticals and relates to a compound represented by formula (IV) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a somatostatin analogue composition for radiopharmaceutical use, in particular for diagnostic or therapeutic use. More specifically the somatostatin analogue is a receptor-selective somatostatin peptide antagonist.

Abstract: The present disclosure relates to a radioactive polypeptide conjugate drug and for use thereof in nuclear medicine as a tracer, an imaging agent, and for treating various disease states associated with tumors is provided.

Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.

Abstract: A peptide-urea derivative, a pharmaceutical composition containing same and an application thereof are provided, the derivative being as shown in formula I. The derivative can be used for preoperative imaging diagnosis and grading of PSMA-positive prostate cancer, and can also be used for the treatment of various types and stages of prostate cancer, achieving the integration of diagnosis and treatment, and having broad application prospects.

Abstract: The disclosure relates to radioimmunotherapy for bladder cancer using an antibody or antibody fragment that specifically binds CUB domain-containing protein 1 (CDCP1). The disclosure also relates to use of a diagnostic radioisotope-labeled anti-CDCP1 antibody or CDCP1-binding fragment thereof for radionuclide imaging of CDCP1 expression in vivo in bladder cancer patients.

Abstract: The disclosure relates to radioimmunotherapy for prostate cancer using an antibody or antibody fragment that specifically binds CUB domain-containing protein 1 (CDCP1). The disclosure further related to use of a diagnostic radioisotope-labeled anti-CDCP1 antibody or CDCP1-binding fragment thereof for radionuclide imaging of CDCP1 expression in vivo. in prostate cancer patients.

Abstract: The present invention provides in certain embodiments a carcinoma-targeting conjugate comprising Formula I: T-L-X wherein T is a SSTR2 targeting ligand, L is a linker, and X is a chelator, for the therapeutic treatment of cancer, and methods of use thereof.

Abstract: A radiotherapy source for treating a tumor, which includes a flexible core impermeable to radon and a polymer coating on the flexible core. The polymer coating is impermeable to radium, and allows diffusion of radon therethrough. The radiotherapy source also includes alpha-emitting radium radionuclides in the polymer coating or between the flexible core and the polymer coating.

Abstract: The present invention is a physical pathogen reduction method and apparatus for controlling or eliminating transfusion-transmittable infections. This purely physical technique does not involve the use of heat, chemicals and/or irradiation, each of which has significant drawbacks in the pathogen reduction of human plasma. The invention inactivates both nonenveloped and enveloped viruses as well as pathogenic bacteria and parasites in units of human plasma, while retaining the natural biological activity. integrity and potency of the treated plasma. The method uses critical, near-critical or supercritical fluids for viral and pathogen reduction of units of donor blood plasma, using novel blood plasma bags. The apparatus is in the form of a bench-top or mobile transportable unit, which can be used in hospitals, blood banks, medical facilities and hot zones in developing countries for the clearance of viruses from human plasma.

Abstract: A pasteurization unit and process for pasteurization of products such as cannabis and hemp.

Abstract: The present invention relates to a system for decontaminating an object. The system comprises a power source, and at least one decontamination area, which includes one or more light sources that emit UV-C radiation to decontaminate the object's surface. In one embodiment, the device comprises the power source; and the at least one decontamination area. In another embodiment, the object comprises the power source; and the at least one decontamination area. In this embodiment, the object further includes a contact area which can become contaminated; and the decontamination area is located within another portion of the object, and is accessible only when the object has undergone a transformation from one use state to another.

Abstract: Apparatuses are disclosed having an ultraviolet lamp, a base supporting the lamp and a support structure coupled to the base. In some cases, the apparatuses include an automated actuator for moving the base and the lamp relative to the support structure and program instructions for activating the automated actuator such that the base and the lamp are repositioned relative to the support structure, sometimes continuously or periodically, while the lamp is emitting ultraviolet light. In other cases, the apparatuses include a reflector arranged along a longitudinal side of the lamp, an automated actuator for providing rotational movement of the reflector relative to the support structure, and program instructions for activating the automated actuator such that the reflector is repositioned relative to the support structure while the lamp is emitting ultraviolet light.

Abstract: A puck is made of a porous resilient material and is held in a housing to comprise a cable swipe cassette. The puck holds fluid in the porous material, and there is a bore through the puck. A cable is routed through the bore so that when the cable is pulled through the bore the exterior surface of the cable is wetted with the fluid. The fluid can have an antimicrobial effect so as to disinfect the cable.

Abstract: Air decontamination formulations are disclosed comprising approximately 28% to approximately 38% by weight of the formulation of dipropylene glycol; approximately 0.12% to approximately 0.43% by weight of the formulation of an odor neutralizing cationic surfactant; approximately 28% to approximately 50% by weight of the formulation of an alcohol, preferably ethanol; and approximately 14% to approximately 33% by weight of the formulation of water. The disclosed air decontamination formulations sanitize or disinfect a volume of air less than or equal to 25 m3 in 0.1 to 5 minutes by providing equal to or greater than a 3 log10 reduction of aerosolized bacteria, including Staphylococcus aureus and Klebsiella pneumoniae, and aerosolized enveloped viruses, including Phi6.

Abstract: Space purification device (1000) of the present disclosure includes an electrolytic bath, electrode part (210), a mixing bath, hypochlorous acid water supply part (228), water supply part (138), an air blower, purification part (310), and controller (500). Controller (500) includes count part (550) that counts an elapsed time from timing at which generation of hypochlorous acid water of a first concentration in the electrolytic bath is completed, and calculation part (560) that calculates, based on a count time counted by count part (550), a concentration decrease value indicating how much the first concentration of the hypochlorous acid water in the electrolytic bath is decreased. Controller (500) is configured to adjust a supply amount of hypochlorous acid water to be supplied from hypochlorous acid water supply part (228) based on the concentration decrease value.

Abstract: The present invention relates to a light-emitting diode (LED) filament (1) configured to provide LED filament light and comprising an elongated carrier (2) comprising a first surface (3) and a second surface (3?) arranged opposite to the first surface (3). The LED filament (1) further comprises a plurality of first light-emitting diodes (4). LEDs, distributed along the first surface (3) of the elongated carrier (2), the plurality of first LEDs (4) being configured to emit a first LED light having a dominant peak wavelength within a first wavelength range, and a plurality of second light-emitting diodes (5), LEDs, distributed along the second surface (3?) of the elongated carrier (2), the plurality of second LEDs (5) being configured to emit a second LED light having a dominant peak wavelength within a second wavelength range being different from the first wavelength range.

Abstract: The present invention relates to an absorber containing an absorber core having water-absorbent resin particles, in which a diffusion area change ratio measured in the order of (1) to (5) is 0.80 to 1.0.

Abstract: Problem to be solved: To provide a composition for wet indicator excellent in discoloration performance and compatibility, and having suppressed odor. Means for solution: A composition for wet indicator comprising an oily gel containing a liquid oily substance and a gelling agent, a colorant and a water holding agent.

Abstract: The subject invention provides topical therapeutic compositions and methods of their use for enhanced healing of wounds, including burns, and scars of the skin. Specifically, in one embodiment, the subject invention provides materials and methods for reducing the healing time of skin wounds and for reducing the appearance of scars. The subject invention utilizes topical compositions comprising microbial growth by-products and, optionally, a topically-acceptable carrier. In specific embodiments, the microbial growth by-products are biosurfactants.

Abstract: A medical patch can comprise a biocompatible substrate and a dry hydrogel precursor layer on the substrate, the precursor layer comprising an electrophilic-hydrogel precursor having a plurality of electrophilic functional groups and a nucleophilic-hydrogel precursor having a plurality of protonated amine groups and no more than about 2 weight percent water. Both the electrophilic-hydrogel precursor and the nucleophilic-hydrogel precursor are substantially uncrosslinked, and are blended or in direct contact with each other. The medical patches can be formed by coating a melt blend of hydrogel precursors in a dry environment or based on solution coating from a dry, non-aqueous solvent, onto a porous, hydrophilic substrate, such as a compressed gelatin substrate. Flexible medical patches can be formed by methods that include compressing coated substrates, such as with calendering. The medical patches can be used for placement over a bleeding wound or the like and may function as a hemostatic patch.

Abstract: The present invention relates to a medical grade bone cement having at least two mixable components, the bone cement comprising: a first component comprising at least 20% by weight of a first polymer material in which at least 40% of the functional groups are methacrylates; and a second component comprising at least one initiator selected to cause cross-linking of said first polymer material, wherein a balance of said second component comprises at least 40% by weight of a second polymer material that does not react with said initiator; said second component being a paste.

Abstract: Devices and methods that include a structure configured to contact a portion of a mammal's bone; and a coating on at least a portion of the structure, wherein the coating comprises a titanium coating component, a silver coating component, and a nitrogen coating component.

Abstract: Compositions useful in medical procedures are described, such as separating tissue layers, e.g., submucosal tissue layers, for removal. In some examples, the compositions may include a pharmaceutically acceptable carrier fluid and one or more biocompatible materials at least partially or completely dissolved or suspended in the pharmaceutically acceptable carrier fluid. The one or more biocompatible materials may be chosen from polymers, phospholipids, nanoclays, or combinations thereof. Advantageously, the compositions may be formulated as a solution, emulsion, gel, or suspension capable of being injected into tissue.

Abstract: A composition and a method for generating a dermal filler are illustrated. The composition comprises an injectable filler, wherein the injectable filler further comprises a plurality of hyaluronic acids and a sugar alcohol. The method comprises obtaining an injectable filler, diluting the injectable filler using a sugar alcohol, and transferring the diluted injectable filler to a syringe to reduce a particle size of the injectable filler.

Abstract: A system and a method for delivering a dermal filler are illustrated. The system includes a dermal filler, wherein the dermal filler includes an injectable filler, wherein the injectable filler further includes at least a hyaluronic acid and at least a raw material, and a syringe configured to deliver the dermal filler. The method includes obtaining an injectable filler, wherein the injectable filler further comprises at least a hyaluronic acid, modifying the injectable filler by diluting the injectable filler using a raw material, and delivering the modified injectable filler by injecting the modified injectable filler into a patient using a syringe.

Abstract: A method and apparatus for degrading a hypodermal tissue scaffold involves exposing the scaffold to a low-intensity focused ultrasonic beam such as to burst gas vesicles trapped in the silk fibroin from which scaffold is constructed. The rate of degradation van be controlled using ultrasonic beams of varying intensities. In one embodiment, the ultrasonic beams are administered trans-dermally to a hypodermal scaffold.

Abstract: Gamma ray and e-beam irradiation provided efficient sterilization of certain self-assembling peptides (including RADA16 in solution) without substantial degradation of the major peptide, while, e.g., another self-assembly peptide, QLEL12 was significantly degraded following irradiation. Irradiation sterilization enhances the rheological property of, for example, RADA16 hydrogel once applied to tissue at a physiological pH. The rheological property increase can result in higher efficacy in a variety of biomedical applications.

Abstract: A compression and kink resistant tubular implant for nerve repair. The implant includes a tubular biopolymeric membrane and a polymeric supporting filament. Also provided is a shaped compression resistant implant for ridge augmentation in dental surgery. Methods for producing the implants are also provided.

Abstract: Compositions comprising perforated, unseparated amnion/chorion; perforated, separated amnion; and perforated, separated chorion derived from the placenta and methods of preparing and using those compositions are provided. Perforation of placental tissue before or during processing may allow for one or more benefits such as more efficient removal of blood remnants, retention of wound healing and tissue regeneration components, better handling characteristics, or improved healing capacity. The present invention also includes methods of healing a wound of the skin, eye, nerve, tendon, or dura comprising applying the perforated compositions of the invention to the wound.

Abstract: Provided is a method of preparing an ECM material and the product of the method. The method comprises processing the ECM material with a reactive oxygen species or a reactive nitrogen species. Also provided are methods of use of the product.

Abstract: A technique can consistently achieve thicknesses of ?50 ?m for corneal tissue for Descemet stripping automated endothelial keratoplasty (DSAEK). Grafts with thicknesses of ?50 ?m are also known as nanothin DSAEK (NT-DSAEK) grafts. Evidence shows that using thinner DSAEK grafts, particularly NT-DSAEK grafts, can significantly improve visual outcomes. According to an example embodiment, a method for producing a corneal graft includes drying a donor cornea to cause a pre-cut thickness of the donor cornea to decrease. The method includes, concurrently with drying the donor cornea, determining pre-cut thickness measurements for the donor cornea. The method includes, in response to the pre-cut thickness measurements indicating the pre-cut thickness of the donor cornea has decreased to a predetermined value, cutting the donor cornea to a post-cut thickness of ?100 ?m, or more particularly ?50 ?m, to produce a corneal graft.

Abstract: Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component.